Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia

Frontiers in Immunology

Ye Jin¹  Pei-hui Xia¹  Jun Qian¹  Wei Qian²  Zi-jun Xu⁴  Ji-chun Ma⁴  Jiang Lin⁴  Xiang-mei Wen⁴ 

[1] Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China;Department of Otolaryngology-Head and Neck Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China;Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China;The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China;Zhenjiang Clinical Research Center of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China;

关键词: mutation;    TP53;    prognosis;    tumor mutational burden;    tumor-infiltrating immune cells;    acute myeloid leukemia;   

DOI  :  10.3389/fimmu.2021.717527

来源: DOAJ

【 摘 要 】

Acute myeloid leukemia (AML) is a heterogeneous disease related to a broad spectrum of molecular alterations. The successes of immunotherapies treating solid tumors and a deeper understanding of the immune systems of patients with hematologic malignancies have promoted the development of immunotherapies for the treatment of AML. And high tumor mutational burden (TMB) is an emerging predictive biomarker for response to immunotherapy. However, the association of gene mutation in AML with TMB and immunological features still has not been clearly elucidated. In our study, based on The Cancer Genome Atlas (TCGA) and BeatAML cohorts, 20 frequently mutated genes were found to be covered by both datasets in AML. And TP53 mutation was associated with a poor prognosis, and its mutation displayed exclusiveness with other common mutated genes in both datasets. Moreover, TP53 mutation correlated with TMB and the immune microenvironment. Gene Set Enrichment Analysis (GSEA) showed that TP53 mutation upregulated signaling pathways involved in the immune system. In summary, TP53 mutation is frequently mutated in AML, and its mutation is associated with dismal outcome, TMB, and immunological features, which may serve as a biomarker to predict immune response in AML.

【 授权许可】

Unknown